Discovering Novel Immune Biomarkers and Druggable Targets with Seromics

Wednesday, May 15 @ 8:00 am / 11:00 am

"Discovering Novel Immune Biomarkers and Druggable Targets with Seromics"

Tyler Hulett, PhD - CSO, CDI Labs

Seromics, the study of the total secreted antibody repertoire in serum and other bodily fluids,is traditional serology reborn in high-throughput. While the field is still emerging, it is already clear that each individual’s serome is incredibly unique, impossibly complex, and yet surprisingly accessible via proteome microarrays (HuProt™), phage-display immunoprecipitation sequencing (PhIP-Seq, HuScan®, VirScan™), and other new synthetic biology platforms. Seromics experiments have revealed a viral-induced autoimmune cause of multiple sclerosis, pre-treatment autoantibodies associated with checkpoint blockade immunotherapy outcomes, and the demonstration that autoantibodies can mimic inborn errors of immunity – genetic-knockout-like phenotypes only discoverable via antibody profiling. This talk will introduce what might be accomplished via broader application of seromics platforms today and the development needed to interrogate the serome more completely in the future.

REGISTER HERE